Online inquiry

IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13907MR)

This product GTTS-WQ13907MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Fibrodysplasia ossificans prograssiva (FOP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13907MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10430MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ4411MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ10392MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ5716MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ2281MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ11271MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ11060MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ11843MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW